Retinal Thickness Predicts the Risk of Cognitive Decline in Parkinson Disease

Objective This study was undertaken to analyze longitudinal changes of retinal thickness and their predictive value as biomarkers of disease progression in idiopathic Parkinson's disease (iPD). Methods Patients with Lewy body diseases were enrolled and prospectively evaluated at 3 years, includ...

Full description

Saved in:
Bibliographic Details
Published inAnnals of neurology Vol. 89; no. 1; pp. 165 - 176
Main Authors Murueta‐Goyena, Ane, Del Pino, Rocío, Galdós, Marta, Arana, Begoña, Acera, Marian, Carmona‐Abellán, Mar, Fernández‐Valle, Tamara, Tijero, Beatriz, Lucas‐Jiménez, Olaia, Ojeda, Natalia, Ibarretxe‐Bilbao, Naroa, Peña, Javier, Cortes, Jesus, Ayala, Unai, Barrenechea, Maitane, Gómez‐Esteban, Juan Carlos, Gabilondo, Iñigo
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 01.01.2021
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Objective This study was undertaken to analyze longitudinal changes of retinal thickness and their predictive value as biomarkers of disease progression in idiopathic Parkinson's disease (iPD). Methods Patients with Lewy body diseases were enrolled and prospectively evaluated at 3 years, including patients with iPD (n = 42), dementia with Lewy bodies (n = 4), E46K‐SNCA mutation carriers (n = 4), and controls (n = 17). All participants underwent Spectralis retinal optical coherence tomography and Montreal Cognitive Assessment, and Unified Parkinson's Disease Rating Scale score was obtained in patients. Macular ganglion cell–inner plexiform layer complex (GCIPL) and peripapillary retinal nerve fiber layer (pRNFL) thickness reduction rates were estimated with linear mixed models. Risk ratios were calculated to evaluate the association between baseline GCIPL and pRNFL thicknesses and the risk of subsequent cognitive and motor worsening, using clinically meaningful cutoffs. Results GCIPL thickness in the parafoveal region (1‐ to 3‐mm ring) presented the largest reduction rate. The annualized atrophy rate was 0.63μm in iPD patients and 0.23μm in controls (p < 0.0001). iPD patients with lower parafoveal GCIPL and pRNFL thickness at baseline presented an increased risk of cognitive decline at 3 years (relative risk [RR] = 3.49, 95% confidence interval [CI] = 1.10–11.1, p = 0.03 and RR = 3.28, 95% CI = 1.03–10.45, p = 0.045, respectively). We did not identify significant associations between retinal thickness and motor deterioration. Interpretation Our results provide evidence of the potential use of optical coherence tomography–measured parafoveal GCIPL thickness to monitor neurodegeneration and to predict the risk of cognitive worsening over time in iPD. ANN NEUROL 2021;89:165–176
AbstractList ObjectiveThis study was undertaken to analyze longitudinal changes of retinal thickness and their predictive value as biomarkers of disease progression in idiopathic Parkinson's disease (iPD).MethodsPatients with Lewy body diseases were enrolled and prospectively evaluated at 3 years, including patients with iPD (n = 42), dementia with Lewy bodies (n = 4), E46K‐SNCA mutation carriers (n = 4), and controls (n = 17). All participants underwent Spectralis retinal optical coherence tomography and Montreal Cognitive Assessment, and Unified Parkinson's Disease Rating Scale score was obtained in patients. Macular ganglion cell–inner plexiform layer complex (GCIPL) and peripapillary retinal nerve fiber layer (pRNFL) thickness reduction rates were estimated with linear mixed models. Risk ratios were calculated to evaluate the association between baseline GCIPL and pRNFL thicknesses and the risk of subsequent cognitive and motor worsening, using clinically meaningful cutoffs.ResultsGCIPL thickness in the parafoveal region (1‐ to 3‐mm ring) presented the largest reduction rate. The annualized atrophy rate was 0.63μm in iPD patients and 0.23μm in controls (p < 0.0001). iPD patients with lower parafoveal GCIPL and pRNFL thickness at baseline presented an increased risk of cognitive decline at 3 years (relative risk [RR] = 3.49, 95% confidence interval [CI] = 1.10–11.1, p = 0.03 and RR = 3.28, 95% CI = 1.03–10.45, p = 0.045, respectively). We did not identify significant associations between retinal thickness and motor deterioration.InterpretationOur results provide evidence of the potential use of optical coherence tomography–measured parafoveal GCIPL thickness to monitor neurodegeneration and to predict the risk of cognitive worsening over time in iPD. ANN NEUROL 2021;89:165–176
This study was undertaken to analyze longitudinal changes of retinal thickness and their predictive value as biomarkers of disease progression in idiopathic Parkinson's disease (iPD). Patients with Lewy body diseases were enrolled and prospectively evaluated at 3 years, including patients with iPD (n = 42), dementia with Lewy bodies (n = 4), E46K-SNCA mutation carriers (n = 4), and controls (n = 17). All participants underwent Spectralis retinal optical coherence tomography and Montreal Cognitive Assessment, and Unified Parkinson's Disease Rating Scale score was obtained in patients. Macular ganglion cell-inner plexiform layer complex (GCIPL) and peripapillary retinal nerve fiber layer (pRNFL) thickness reduction rates were estimated with linear mixed models. Risk ratios were calculated to evaluate the association between baseline GCIPL and pRNFL thicknesses and the risk of subsequent cognitive and motor worsening, using clinically meaningful cutoffs. GCIPL thickness in the parafoveal region (1- to 3-mm ring) presented the largest reduction rate. The annualized atrophy rate was 0.63μm in iPD patients and 0.23μm in controls (p < 0.0001). iPD patients with lower parafoveal GCIPL and pRNFL thickness at baseline presented an increased risk of cognitive decline at 3 years (relative risk [RR] = 3.49, 95% confidence interval [CI] = 1.10-11.1, p = 0.03 and RR = 3.28, 95% CI = 1.03-10.45, p = 0.045, respectively). We did not identify significant associations between retinal thickness and motor deterioration. Our results provide evidence of the potential use of optical coherence tomography-measured parafoveal GCIPL thickness to monitor neurodegeneration and to predict the risk of cognitive worsening over time in iPD. ANN NEUROL 2021;89:165-176.
Objective This study was undertaken to analyze longitudinal changes of retinal thickness and their predictive value as biomarkers of disease progression in idiopathic Parkinson's disease (iPD). Methods Patients with Lewy body diseases were enrolled and prospectively evaluated at 3 years, including patients with iPD (n = 42), dementia with Lewy bodies (n = 4), E46K‐SNCA mutation carriers (n = 4), and controls (n = 17). All participants underwent Spectralis retinal optical coherence tomography and Montreal Cognitive Assessment, and Unified Parkinson's Disease Rating Scale score was obtained in patients. Macular ganglion cell–inner plexiform layer complex (GCIPL) and peripapillary retinal nerve fiber layer (pRNFL) thickness reduction rates were estimated with linear mixed models. Risk ratios were calculated to evaluate the association between baseline GCIPL and pRNFL thicknesses and the risk of subsequent cognitive and motor worsening, using clinically meaningful cutoffs. Results GCIPL thickness in the parafoveal region (1‐ to 3‐mm ring) presented the largest reduction rate. The annualized atrophy rate was 0.63μm in iPD patients and 0.23μm in controls (p < 0.0001). iPD patients with lower parafoveal GCIPL and pRNFL thickness at baseline presented an increased risk of cognitive decline at 3 years (relative risk [RR] = 3.49, 95% confidence interval [CI] = 1.10–11.1, p = 0.03 and RR = 3.28, 95% CI = 1.03–10.45, p = 0.045, respectively). We did not identify significant associations between retinal thickness and motor deterioration. Interpretation Our results provide evidence of the potential use of optical coherence tomography–measured parafoveal GCIPL thickness to monitor neurodegeneration and to predict the risk of cognitive worsening over time in iPD. ANN NEUROL 2021;89:165–176
Objective This study was undertaken to analyze longitudinal changes of retinal thickness and their predictive value as biomarkers of disease progression in idiopathic Parkinson's disease (iPD). Methods Patients with Lewy body diseases were enrolled and prospectively evaluated at 3 years, including patients with iPD (n = 42), dementia with Lewy bodies (n = 4), E46K‐ SNCA mutation carriers (n = 4), and controls (n = 17). All participants underwent Spectralis retinal optical coherence tomography and Montreal Cognitive Assessment, and Unified Parkinson's Disease Rating Scale score was obtained in patients. Macular ganglion cell–inner plexiform layer complex (GCIPL) and peripapillary retinal nerve fiber layer (pRNFL) thickness reduction rates were estimated with linear mixed models. Risk ratios were calculated to evaluate the association between baseline GCIPL and pRNFL thicknesses and the risk of subsequent cognitive and motor worsening, using clinically meaningful cutoffs. Results GCIPL thickness in the parafoveal region (1‐ to 3‐mm ring) presented the largest reduction rate. The annualized atrophy rate was 0.63μm in iPD patients and 0.23μm in controls ( p  < 0.0001). iPD patients with lower parafoveal GCIPL and pRNFL thickness at baseline presented an increased risk of cognitive decline at 3 years (relative risk [RR] = 3.49, 95% confidence interval [CI] = 1.10–11.1, p = 0.03 and RR = 3.28, 95% CI = 1.03–10.45, p = 0.045, respectively). We did not identify significant associations between retinal thickness and motor deterioration. Interpretation Our results provide evidence of the potential use of optical coherence tomography–measured parafoveal GCIPL thickness to monitor neurodegeneration and to predict the risk of cognitive worsening over time in iPD. ANN NEUROL 2021;89:165–176
OBJECTIVEThis study was undertaken to analyze longitudinal changes of retinal thickness and their predictive value as biomarkers of disease progression in idiopathic Parkinson's disease (iPD). METHODSPatients with Lewy body diseases were enrolled and prospectively evaluated at 3 years, including patients with iPD (n = 42), dementia with Lewy bodies (n = 4), E46K-SNCA mutation carriers (n = 4), and controls (n = 17). All participants underwent Spectralis retinal optical coherence tomography and Montreal Cognitive Assessment, and Unified Parkinson's Disease Rating Scale score was obtained in patients. Macular ganglion cell-inner plexiform layer complex (GCIPL) and peripapillary retinal nerve fiber layer (pRNFL) thickness reduction rates were estimated with linear mixed models. Risk ratios were calculated to evaluate the association between baseline GCIPL and pRNFL thicknesses and the risk of subsequent cognitive and motor worsening, using clinically meaningful cutoffs. RESULTSGCIPL thickness in the parafoveal region (1- to 3-mm ring) presented the largest reduction rate. The annualized atrophy rate was 0.63μm in iPD patients and 0.23μm in controls (p < 0.0001). iPD patients with lower parafoveal GCIPL and pRNFL thickness at baseline presented an increased risk of cognitive decline at 3 years (relative risk [RR] = 3.49, 95% confidence interval [CI] = 1.10-11.1, p = 0.03 and RR = 3.28, 95% CI = 1.03-10.45, p = 0.045, respectively). We did not identify significant associations between retinal thickness and motor deterioration. INTERPRETATIONOur results provide evidence of the potential use of optical coherence tomography-measured parafoveal GCIPL thickness to monitor neurodegeneration and to predict the risk of cognitive worsening over time in iPD. ANN NEUROL 2021;89:165-176.
Author Cortes, Jesus
Ayala, Unai
Galdós, Marta
Gabilondo, Iñigo
Fernández‐Valle, Tamara
Tijero, Beatriz
Arana, Begoña
Barrenechea, Maitane
Murueta‐Goyena, Ane
Carmona‐Abellán, Mar
Del Pino, Rocío
Peña, Javier
Lucas‐Jiménez, Olaia
Gómez‐Esteban, Juan Carlos
Ojeda, Natalia
Ibarretxe‐Bilbao, Naroa
Acera, Marian
AuthorAffiliation 8 Computational Neuroimaging Group Biocruces Bizkaia Health Research Institute Barakaldo Spain
5 Neurology Department Cruces University Hospital Barakaldo Spain
9 Ikerbasque: The Basque Foundation for Science Bilbao Spain
10 Biomedical Engineering Department, Faculty of Engineering Mondragon University Mondragon Spain
4 Ophthalmology Department Cruces University Hospital Barakaldo Spain
3 International University of La Rioja Logroño Spain
1 Neurodegenerative Diseases Group Biocruces Bizkaia Health Research Institute Barakaldo Spain
2 Department of Physiology University of the Basque Country (Universidad del País Vasco / Euskal Herriko Unibertsitatea) Leioa Spain
6 Department of Neurosciences University of the Basque Country (UPV/EHU) Leioa Spain
7 Department of Methods and Experimental Psychology, Faculty of Psychology and Education University of Deusto Bilbao Spain
AuthorAffiliation_xml – name: 2 Department of Physiology University of the Basque Country (Universidad del País Vasco / Euskal Herriko Unibertsitatea) Leioa Spain
– name: 9 Ikerbasque: The Basque Foundation for Science Bilbao Spain
– name: 3 International University of La Rioja Logroño Spain
– name: 6 Department of Neurosciences University of the Basque Country (UPV/EHU) Leioa Spain
– name: 8 Computational Neuroimaging Group Biocruces Bizkaia Health Research Institute Barakaldo Spain
– name: 10 Biomedical Engineering Department, Faculty of Engineering Mondragon University Mondragon Spain
– name: 4 Ophthalmology Department Cruces University Hospital Barakaldo Spain
– name: 1 Neurodegenerative Diseases Group Biocruces Bizkaia Health Research Institute Barakaldo Spain
– name: 5 Neurology Department Cruces University Hospital Barakaldo Spain
– name: 7 Department of Methods and Experimental Psychology, Faculty of Psychology and Education University of Deusto Bilbao Spain
Author_xml – sequence: 1
  givenname: Ane
  orcidid: 0000-0002-9808-6943
  surname: Murueta‐Goyena
  fullname: Murueta‐Goyena, Ane
  email: ane.muruetagoyena@osakidetza.eus
  organization: University of the Basque Country (Universidad del País Vasco / Euskal Herriko Unibertsitatea)
– sequence: 2
  givenname: Rocío
  surname: Del Pino
  fullname: Del Pino, Rocío
  organization: International University of La Rioja
– sequence: 3
  givenname: Marta
  surname: Galdós
  fullname: Galdós, Marta
  organization: Cruces University Hospital
– sequence: 4
  givenname: Begoña
  surname: Arana
  fullname: Arana, Begoña
  organization: Cruces University Hospital
– sequence: 5
  givenname: Marian
  surname: Acera
  fullname: Acera, Marian
  organization: Biocruces Bizkaia Health Research Institute
– sequence: 6
  givenname: Mar
  orcidid: 0000-0002-3765-1005
  surname: Carmona‐Abellán
  fullname: Carmona‐Abellán, Mar
  organization: Biocruces Bizkaia Health Research Institute
– sequence: 7
  givenname: Tamara
  surname: Fernández‐Valle
  fullname: Fernández‐Valle, Tamara
  organization: University of the Basque Country (UPV/EHU)
– sequence: 8
  givenname: Beatriz
  surname: Tijero
  fullname: Tijero, Beatriz
  organization: Cruces University Hospital
– sequence: 9
  givenname: Olaia
  orcidid: 0000-0002-7715-3764
  surname: Lucas‐Jiménez
  fullname: Lucas‐Jiménez, Olaia
  organization: University of Deusto
– sequence: 10
  givenname: Natalia
  surname: Ojeda
  fullname: Ojeda, Natalia
  organization: University of Deusto
– sequence: 11
  givenname: Naroa
  surname: Ibarretxe‐Bilbao
  fullname: Ibarretxe‐Bilbao, Naroa
  organization: University of Deusto
– sequence: 12
  givenname: Javier
  surname: Peña
  fullname: Peña, Javier
  organization: University of Deusto
– sequence: 13
  givenname: Jesus
  surname: Cortes
  fullname: Cortes, Jesus
  organization: Ikerbasque: The Basque Foundation for Science
– sequence: 14
  givenname: Unai
  surname: Ayala
  fullname: Ayala, Unai
  organization: Mondragon University
– sequence: 15
  givenname: Maitane
  surname: Barrenechea
  fullname: Barrenechea, Maitane
  organization: Mondragon University
– sequence: 16
  givenname: Juan Carlos
  surname: Gómez‐Esteban
  fullname: Gómez‐Esteban, Juan Carlos
  organization: University of the Basque Country (UPV/EHU)
– sequence: 17
  givenname: Iñigo
  orcidid: 0000-0001-6045-2840
  surname: Gabilondo
  fullname: Gabilondo, Iñigo
  organization: Ikerbasque: The Basque Foundation for Science
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33098308$$D View this record in MEDLINE/PubMed
BookMark eNp1kU1PGzEURa0K1ATaRf8AssSmXQz4c5zZIEWhUCTaRhFdWx7Pc2IysYM9oeLfMyEUUSRWb_GOjq7uPUB7IQZA6AslJ5QQdmqCOWGyEuIDGlLJaTFiotpDQ8JLUUjKxQAd5HxLCKlKSj6iAeekGnEyGqKfM-h8MC2-WXi7DJAzniZovO0y7haAZz4vcXR4EufBd_4e8DnY1gfAPuCpSUsfcgz43GcwGT6hfWfaDJ-f7yH6c_H9ZvKjuP59eTUZXxdWCC4KxUjNja2ZNGVtKxBM9ekZVXXdVMZJVwolHVEMStsQ4ShTjapq52wNhFvGD9HZzrve1CtoLIQumVavk1-Z9KCj8fr_T_ALPY_3WilZlqLsBV-fBSnebSB3euWzhbY1AeImayakoH1xI9Wjx2_Q27hJfWVbShFRccm21LcdZVPMOYF7CUOJ3o6k-5H000g9e_Q6_Qv5b5UeON0Bf30LD--b9PjXeKd8BDFhnU4
CitedBy_id crossref_primary_10_1038_s41467_024_49949_9
crossref_primary_10_1016_j_ajpath_2024_01_017
crossref_primary_10_1016_j_ebiom_2023_104615
crossref_primary_10_1016_j_neurobiolaging_2023_01_015
crossref_primary_10_1016_j_parkreldis_2024_107037
crossref_primary_10_3390_biom13020218
crossref_primary_10_3233_JPD_212775
crossref_primary_10_1038_s41531_024_00637_x
crossref_primary_10_3390_biomedicines11020573
crossref_primary_10_3233_JPD_223481
crossref_primary_10_1093_brain_awac317
crossref_primary_10_1016_j_ajo_2023_10_005
crossref_primary_10_1097_MD_0000000000035354
crossref_primary_10_1111_jnp_12307
crossref_primary_10_1007_s00415_021_10703_6
crossref_primary_10_1016_j_euroneuro_2021_10_374
crossref_primary_10_1016_j_parkreldis_2024_106063
crossref_primary_10_1186_s41983_023_00701_y
crossref_primary_10_3390_jimaging8050139
crossref_primary_10_1016_j_jns_2021_120015
crossref_primary_10_3390_proteomes10010004
crossref_primary_10_1016_j_nbd_2023_106379
crossref_primary_10_3390_jcm11092624
crossref_primary_10_1186_s40478_024_01782_3
crossref_primary_10_17116_jnevro20221221125
crossref_primary_10_1016_j_parkreldis_2021_10_005
crossref_primary_10_1002_mds_28602
crossref_primary_10_1136_bmjophth_2022_001061
crossref_primary_10_3389_fnins_2021_708700
crossref_primary_10_1136_jnnp_2022_329342
crossref_primary_10_1007_s00415_023_11720_3
crossref_primary_10_1007_s11065_022_09551_6
crossref_primary_10_1038_s41531_023_00611_z
crossref_primary_10_1007_s11055_023_01487_5
crossref_primary_10_1007_s11910_024_01349_8
crossref_primary_10_1038_s41433_023_02438_7
crossref_primary_10_3389_fnins_2022_928980
crossref_primary_10_1038_s41582_022_00618_9
crossref_primary_10_1136_jnnp_2023_331083
crossref_primary_10_1002_cne_25481
crossref_primary_10_1016_j_wneu_2023_06_048
Cites_doi 10.1002/ana.25696
10.1002/mds.27392
10.1002/mds.27728
10.1212/WNL.41.8.1200
10.1016/j.parkreldis.2019.04.023
10.3233/JPD-171184
10.1111/j.1532-5415.2005.53221.x
10.1371/journal.pone.0034823
10.2741/1171
10.1007/s10654-018-00478-y
10.1097/IAE.0000000000002641
10.1093/brain/aww175
10.1037/a0012949
10.3233/JPD-140470
10.1093/brain/110.6.1675
10.1001/archneur.59.8.1249
10.1167/iovs.16-20025
10.1002/ana.10795
10.1016/j.ophtha.2013.07.021
10.1093/brain/awt360
10.1212/CPJ.0000000000000719
10.1136/jnnp.47.7.673
10.1016/S1388-2457(99)00223-0
10.1212/WNL.40.11.1710
10.1001/archneurol.2009.295
10.1212/WNL.0000000000006157
10.1016/j.jns.2011.07.047
10.1212/WNL.0000000000000842
10.1167/iovs.16-20460
10.18637/jss.v067.i01
10.1167/iovs.17-23230
10.1111/aos.14291
10.1001/archneur.1984.04050170031011
10.1093/brain/awm111
10.1038/s41598-019-48388-7
10.1212/WNL.0000000000009107
10.1155/2012/384875
10.1001/jamaophthalmol.2020.0959
10.1007/s10792-018-0934-y
10.1007/s00401-018-01956-z
10.1002/mds.27914
10.1002/mds.20914
10.1002/acn3.767
ContentType Journal Article
Copyright 2020 The Authors. published by Wiley Periodicals LLC on behalf of American Neurological Association.
2020 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
2020. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2020 The Authors. published by Wiley Periodicals LLC on behalf of American Neurological Association.
– notice: 2020 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
– notice: 2020. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID 24P
WIN
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7TK
7U7
C1K
K9.
7X8
5PM
DOI 10.1002/ana.25944
DatabaseName Open Access: Wiley-Blackwell Open Access Journals
Wiley Online Library Journals
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Neurosciences Abstracts
Toxicology Abstracts
Environmental Sciences and Pollution Management
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
ProQuest Health & Medical Complete (Alumni)
Toxicology Abstracts
Neurosciences Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList ProQuest Health & Medical Complete (Alumni)
MEDLINE

CrossRef
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: 24P
  name: Open Access: Wiley-Blackwell Open Access Journals
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Retinal Thinning and Cognition
EISSN 1531-8249
EndPage 176
ExternalDocumentID 10_1002_ana_25944
33098308
ANA25944
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Michael J. Fox Foundation for Parkinson's Research
  funderid: RRIA 2014 (Rapid Response Innovation Awards) Progr
– fundername: Instituto de Salud Carlos III and co‐funded by European Union (ERDF/ESF, "A way to make Europe"/"Investing in your future")
  funderid: Juan Rodes grant JR15/00008; PI14/00679; PI16/00005
– fundername: Osasun Saila, Eusko Jaurlaritzako
  funderid: 2016111009; 2020333033
– fundername: ;
  grantid: 2016111009; 2020333033
– fundername: ;
  grantid: RRIA 2014 (Rapid Response Innovation Awards) Progr
– fundername: Instituto de Salud Carlos III and co‐funded by European Union (ERDF/ESF, "A way to make Europe"/"Investing in your future")
  grantid: Juan Rodes grant JR15/00008; PI14/00679; PI16/00005
GroupedDBID ---
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
1CY
1L6
1OB
1OC
1ZS
23M
24P
2QL
31~
33P
3O-
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5VS
66C
6J9
6P2
6PF
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAEJM
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AAQQT
AASGY
AAWTL
AAXRX
AAZKR
ABCQN
ABCUV
ABEML
ABIJN
ABIVO
ABJNI
ABLJU
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACBMB
ACBWZ
ACCFJ
ACCZN
ACGFO
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACRZS
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFAZI
AFBPY
AFFNX
AFFPM
AFGKR
AFPWT
AFRAH
AFZJQ
AHBTC
AHMBA
AI.
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
AJJEV
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR1
DR2
DRFUL
DRMAN
DRSTM
EBS
EJD
EMOBN
F00
F01
F04
F5P
F8P
FEDTE
FUBAC
FYBCS
G-S
G.N
GNP
GODZA
GOZPB
GRPMH
H.X
HBH
HF~
HGLYW
HHY
HHZ
HVGLF
HZ~
IX1
J0M
J5H
JPC
KBYEO
KD1
KQQ
L7B
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LXL
LXN
LXY
LYRES
M6M
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N4W
N9A
NF~
NNB
O66
O9-
OHT
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.-
Q.N
Q11
QB0
QRW
R.K
RIWAO
RJQFR
ROL
RWD
RWI
RX1
SAMSI
SJN
SUPJJ
TEORI
UB1
V2E
V8K
V9Y
VH1
W8V
W99
WBKPD
WH7
WHWMO
WIB
WIH
WIJ
WIK
WIN
WJL
WOHZO
WQJ
WRC
WUP
WVDHM
WXI
WXSBR
X7M
XG1
XJT
XPP
XSW
XV2
YOC
YQJ
ZGI
ZRF
ZRR
ZXP
ZZTAW
~IA
~WT
~X8
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7TK
7U7
C1K
K9.
7X8
5PM
ID FETCH-LOGICAL-c4434-720b3acb25a6bc9e427594217bbd9af5f6475f072e6cd04f127d79bffcbe03c23
IEDL.DBID 24P
ISSN 0364-5134
IngestDate Tue Sep 17 21:07:04 EDT 2024
Fri Aug 16 09:32:08 EDT 2024
Fri Aug 30 23:48:59 EDT 2024
Fri Aug 23 02:59:09 EDT 2024
Sat Sep 28 08:24:20 EDT 2024
Sat Aug 24 01:05:28 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Attribution-NonCommercial
2020 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4434-720b3acb25a6bc9e427594217bbd9af5f6475f072e6cd04f127d79bffcbe03c23
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-3765-1005
0000-0002-7715-3764
0000-0001-6045-2840
0000-0002-9808-6943
OpenAccessLink https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fana.25944
PMID 33098308
PQID 2470493527
PQPubID 946345
PageCount 12
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_7756646
proquest_miscellaneous_2454113487
proquest_journals_2470493527
crossref_primary_10_1002_ana_25944
pubmed_primary_33098308
wiley_primary_10_1002_ana_25944_ANA25944
PublicationCentury 2000
PublicationDate January 2021
PublicationDateYYYYMMDD 2021-01-01
PublicationDate_xml – month: 01
  year: 2021
  text: January 2021
PublicationDecade 2020
PublicationPlace Hoboken, USA
PublicationPlace_xml – name: Hoboken, USA
– name: United States
– name: Minneapolis
PublicationTitle Annals of neurology
PublicationTitleAlternate Ann Neurol
PublicationYear 2021
Publisher John Wiley & Sons, Inc
Wiley Subscription Services, Inc
Publisher_xml – name: John Wiley & Sons, Inc
– name: Wiley Subscription Services, Inc
References 2018; 141
1984; 41
2002; 59
2019; 9
2015; 5
2012; 2012
2019; 6
1984; 47
2020; 40
2019; 34
2019; 39
2020; 35
2000; 111
2020; 10
2013; 120
2020; 98
1998; 21
2014; 83
2011; 310
2016; 57
2014; 137
1990; 40
2010; 67
2004; 55
2015; 67
2018; 8
1987; 110
2019; 64
2017; 58
2006; 21
2020; 94
1991; 41
2003; 8
2007; 130
2019; 137
2020; 138
2018; 91
2005; 53
2016; 63
2016; 139
2008; 22
2020; 87
2012; 7
2018; 33
2018; 59
e_1_2_8_28_1
e_1_2_8_29_1
e_1_2_8_24_1
Ojeda N (e_1_2_8_31_1) 2016; 63
e_1_2_8_47_1
e_1_2_8_25_1
e_1_2_8_46_1
e_1_2_8_26_1
e_1_2_8_27_1
e_1_2_8_3_1
e_1_2_8_5_1
e_1_2_8_4_1
e_1_2_8_7_1
e_1_2_8_6_1
e_1_2_8_9_1
e_1_2_8_8_1
e_1_2_8_20_1
e_1_2_8_43_1
e_1_2_8_21_1
e_1_2_8_42_1
e_1_2_8_22_1
e_1_2_8_45_1
e_1_2_8_23_1
e_1_2_8_44_1
e_1_2_8_41_1
e_1_2_8_40_1
e_1_2_8_17_1
e_1_2_8_18_1
e_1_2_8_39_1
e_1_2_8_19_1
e_1_2_8_13_1
e_1_2_8_36_1
e_1_2_8_14_1
e_1_2_8_35_1
e_1_2_8_15_1
e_1_2_8_38_1
e_1_2_8_16_1
e_1_2_8_37_1
Lanskey JH (e_1_2_8_2_1) 2018; 141
Diederich NJ (e_1_2_8_10_1) 1998; 21
e_1_2_8_32_1
e_1_2_8_11_1
e_1_2_8_34_1
e_1_2_8_12_1
e_1_2_8_33_1
e_1_2_8_30_1
References_xml – volume: 34
  start-page: 1315
  year: 2019
  end-page: 1324
  article-title: Parafoveal thinning of inner retina is associated with visual dysfunction in Lewy body diseases
  publication-title: Mov Disord
– volume: 59
  start-page: 1249
  year: 2002
  end-page: 1252
  article-title: Progressive worsening of spatial and chromatic processing deficits in Parkinson disease
  publication-title: Arch Neurol
– volume: 35
  start-page: 349
  year: 2020
  end-page: 354
  article-title: Retina thickness as a marker of neurodegeneration in prodromal lewy body disease
  publication-title: Mov Disord
– volume: 8
  start-page: s992
  year: 2003
  end-page: s997
  article-title: Visual‐spatial ability in Parkinson's disease
  publication-title: Front Biosci
– volume: 5
  start-page: 125
  year: 2015
  end-page: 130
  article-title: Abnormal visual contrast acuity in Parkinson's disease
  publication-title: J Parkinson Dis
– volume: 67
  start-page: 48
  year: 2015
  article-title: Fitting linear mixed‐effects models using lme4
  publication-title: J Stat Softw
– volume: 91
  start-page: e1003
  year: 2018
  end-page: e1012
  article-title: Retinal thinning associates with nigral dopaminergic loss in de novo Parkinson disease
  publication-title: Neurology
– volume: 87
  start-page: 533
  year: 2020
  end-page: 546
  article-title: Visual dysfunction of the superior colliculus in de novo parkinsonian patients
  publication-title: Ann Neurol
– volume: 22
  start-page: 729
  year: 2008
  end-page: 737
  article-title: Visuospatial deficits predict rate of cognitive decline in autopsy‐verified dementia with Lewy bodies
  publication-title: Neuropsychology
– volume: 33
  start-page: 1315
  year: 2018
  end-page: 1324
  article-title: Phosphorylated α‐synuclein in the retina is a biomarker of Parkinson's disease pathology severity
  publication-title: Mov Disord
– volume: 310
  start-page: 86
  year: 2011
  end-page: 89
  article-title: Initial neuropsychological impairments in patients with the E46K mutation of the alpha‐synuclein gene (PARK 1)
  publication-title: J Neurol Sci
– volume: 130
  start-page: 1787
  year: 2007
  end-page: 1798
  article-title: Evolution of cognitive dysfunction in an incident Parkinson's disease cohort
  publication-title: Brain
– volume: 111
  start-page: 66
  year: 2000
  end-page: 74
  article-title: Visual contrast response functions in Parkinson's disease: evidence from electroretinograms, visually evoked potentials and psychophysics
  publication-title: Clin Neurophysiol
– volume: 47
  start-page: 673
  year: 1984
  end-page: 678
  article-title: Visual fatigue and visual evoked potentials in multiple sclerosis, glaucoma, ocular hypertension and Parkinson's disease
  publication-title: J Neurol Neurosurg Psychiatry
– volume: 40
  start-page: 1483
  year: 2020
  end-page: 1491
  article-title: Characterization by fractal dimension analysis of the retinal capillary network in Parkinson disease
  publication-title: Retina
– volume: 94
  start-page: 481
  year: 2020
  end-page: 494
  article-title: Disease modification and biomarker development in Parkinson disease: revision or reconstruction?
  publication-title: Neurology
– volume: 58
  start-page: 1151
  year: 2017
  end-page: 1157
  article-title: Evaluation of progressive visual dysfunction and retinal degeneration in patients with Parkinson's disease
  publication-title: Investig Ophthalmol Vis Sci
– volume: 41
  start-page: 485
  year: 1984
  end-page: 490
  article-title: Visuospatial impairment in Parkinson's disease. Role of perceptual and motor factors
  publication-title: Arch Neurol
– volume: 67
  start-page: 64
  year: 2010
  end-page: 70
  article-title: The clinically important difference on the Unified Parkinson's Disease Rating Scale
  publication-title: Arch Neurol
– volume: 137
  start-page: 379
  year: 2019
  end-page: 395
  article-title: Retinal alpha‐synuclein deposits in Parkinson's disease patients and animal models
  publication-title: Acta Neuropathol
– volume: 8
  start-page: 85
  year: 2018
  end-page: 92
  article-title: Progressive changes in the retinal structure of patients with Parkinson's disease
  publication-title: J Parkinsons Dis
– volume: 110
  start-page: 1675
  year: 1987
  end-page: 1698
  article-title: Visual dysfunction in Parkinson's disease. Loss in spatiotemporal contrast sensitivity
  publication-title: Brain
– volume: 21
  start-page: 289
  year: 1998
  end-page: 295
  article-title: Poor visual discrimination and visual hallucinations in Parkinson's disease
  publication-title: Clin Neuropharmacol
– volume: 64
  start-page: 40
  year: 2019
  end-page: 49
  article-title: Retinal layers in Parkinson's disease: a meta‐analysis of spectral‐domain optical coherence tomography studies
  publication-title: Parkinsonism Relat Disord
– volume: 141
  start-page: 2545
  year: 2018
  end-page: 2560
  article-title: Can neuroimaging predict dementia in Parkinson's disease?
  publication-title: Brain
– volume: 57
  start-page: 5696
  year: 2016
  end-page: 5704
  article-title: Visual contrast sensitivity in early‐stage Parkinson's disease
  publication-title: Investig Ophthalmol Vis Sci
– volume: 98
  start-page: e479
  year: 2020
  end-page: e486
  article-title: Longitudinal changes in the thickness of the ganglion cell‐inner plexiform layer in patients with hypertension: a 4‐year prospective observational study
  publication-title: Acta Ophthalmol
– volume: 83
  start-page: 1253
  year: 2014
  end-page: 1260
  article-title: Predictors of dementia in Parkinson disease: a prospective cohort study
  publication-title: Neurology
– volume: 139
  start-page: 2827
  year: 2016
  end-page: 2843
  article-title: Visual dysfunction in Parkinson's disease
  publication-title: Brain
– volume: 120
  start-page: 2485
  year: 2013
  end-page: 2492
  article-title: Impact of age‐related change of retinal nerve fiber layer and macular thicknesses on evaluation of glaucoma progression
  publication-title: Ophthalmology
– volume: 34
  start-page: 141
  year: 2019
  end-page: 152
  article-title: Vision loss and 12‐year risk of dementia in older adults: the 3C cohort study
  publication-title: Eur J Epidemiol
– volume: 6
  start-page: 902
  year: 2019
  end-page: 912
  article-title: Neural correlates of early cognitive dysfunction in Parkinson's disease
  publication-title: Ann Clin Transl Neurol
– volume: 39
  start-page: 1255
  year: 2019
  end-page: 1262
  article-title: Functional and morphological assessment of ocular structures and follow‐up of patients with early‐stage Parkinson's disease
  publication-title: Int Ophthalmol
– volume: 137
  start-page: 849
  year: 2014
  end-page: 859
  article-title: Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations
  publication-title: Brain
– volume: 53
  start-page: 695
  year: 2005
  end-page: 699
  article-title: The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment
  publication-title: J Am Geriatr Soc
– volume: 63
  start-page: 488
  year: 2016
  end-page: 496
  article-title: Montreal Cognitive Assessment test: normalization and standardization for Spanish population
  publication-title: Rev Neurol
– volume: 21
  start-page: 1200
  year: 2006
  end-page: 1207
  article-title: Minimal clinically important change on the Unified Parkinson's Disease Rating Scale
  publication-title: Mov Disord
– volume: 40
  start-page: 1710
  year: 1990
  end-page: 1714
  article-title: Spatiotemporal contrast sensitivity differs in normal aging and Parkinson's disease
  publication-title: Neurology
– volume: 7
  year: 2012
  article-title: The OSCAR‐IB consensus criteria for retinal OCT quality assessment
  publication-title: PLoS One
– volume: 138
  start-page: 624
  year: 2020
  end-page: 633
  article-title: Association of visual impairment with risk of incident dementia in a Women's Health Initiative population
  publication-title: JAMA Ophthalmol
– volume: 10
  start-page: 29
  year: 2020
  end-page: 39
  article-title: Visual tests predict dementia risk in Parkinson disease
  publication-title: Neurol Clin Pract
– volume: 9
  start-page: 11832
  year: 2019
  article-title: Inner retinal thinning as a biomarker for cognitive impairment in de novo Parkinson's disease
  publication-title: Sci Rep
– volume: 59
  start-page: 4115
  year: 2018
  end-page: 4122
  article-title: Retinal microvascular impairment in the early stages of Parkinson's disease
  publication-title: Investig Ophthalmol Vis Sci
– volume: 41
  start-page: 1200
  year: 1991
  end-page: 1202
  article-title: Spatial contrast sensitivity is reduced in bilateral Parkinson's disease
  publication-title: Neurology
– volume: 2012
  start-page: 384875
  year: 2012
  article-title: Use of physical and intellectual activities and socialization in the management of cognitive decline of aging and in dementia: a review
  publication-title: J Aging Res
– volume: 55
  start-page: 164
  year: 2004
  end-page: 173
  article-title: The new mutation, E46K, of alpha‐synuclein causes Parkinson and Lewy body dementia
  publication-title: Ann Neurol
– ident: e_1_2_8_38_1
  doi: 10.1002/ana.25696
– ident: e_1_2_8_45_1
  doi: 10.1002/mds.27392
– ident: e_1_2_8_21_1
  doi: 10.1002/mds.27728
– ident: e_1_2_8_12_1
  doi: 10.1212/WNL.41.8.1200
– ident: e_1_2_8_23_1
  doi: 10.1016/j.parkreldis.2019.04.023
– ident: e_1_2_8_28_1
  doi: 10.3233/JPD-171184
– ident: e_1_2_8_30_1
  doi: 10.1111/j.1532-5415.2005.53221.x
– ident: e_1_2_8_29_1
  doi: 10.1371/journal.pone.0034823
– ident: e_1_2_8_9_1
  doi: 10.2741/1171
– volume: 141
  start-page: 2545
  year: 2018
  ident: e_1_2_8_2_1
  article-title: Can neuroimaging predict dementia in Parkinson's disease?
  publication-title: Brain
  contributor:
    fullname: Lanskey JH
– ident: e_1_2_8_43_1
  doi: 10.1007/s10654-018-00478-y
– ident: e_1_2_8_46_1
  doi: 10.1097/IAE.0000000000002641
– ident: e_1_2_8_40_1
  doi: 10.1093/brain/aww175
– ident: e_1_2_8_5_1
  doi: 10.1037/a0012949
– volume: 63
  start-page: 488
  year: 2016
  ident: e_1_2_8_31_1
  article-title: Montreal Cognitive Assessment test: normalization and standardization for Spanish population
  publication-title: Rev Neurol
  contributor:
    fullname: Ojeda N
– volume: 21
  start-page: 289
  year: 1998
  ident: e_1_2_8_10_1
  article-title: Poor visual discrimination and visual hallucinations in Parkinson's disease
  publication-title: Clin Neuropharmacol
  contributor:
    fullname: Diederich NJ
– ident: e_1_2_8_14_1
  doi: 10.3233/JPD-140470
– ident: e_1_2_8_7_1
  doi: 10.1093/brain/110.6.1675
– ident: e_1_2_8_11_1
  doi: 10.1001/archneur.59.8.1249
– ident: e_1_2_8_16_1
  doi: 10.1167/iovs.16-20025
– ident: e_1_2_8_4_1
  doi: 10.1002/ana.10795
– ident: e_1_2_8_35_1
  doi: 10.1016/j.ophtha.2013.07.021
– ident: e_1_2_8_39_1
  doi: 10.1093/brain/awt360
– ident: e_1_2_8_19_1
  doi: 10.1212/CPJ.0000000000000719
– ident: e_1_2_8_17_1
  doi: 10.1136/jnnp.47.7.673
– ident: e_1_2_8_13_1
  doi: 10.1016/S1388-2457(99)00223-0
– ident: e_1_2_8_15_1
  doi: 10.1212/WNL.40.11.1710
– ident: e_1_2_8_34_1
  doi: 10.1001/archneurol.2009.295
– ident: e_1_2_8_44_1
  doi: 10.1212/WNL.0000000000006157
– ident: e_1_2_8_6_1
  doi: 10.1016/j.jns.2011.07.047
– ident: e_1_2_8_20_1
  doi: 10.1212/WNL.0000000000000842
– ident: e_1_2_8_27_1
  doi: 10.1167/iovs.16-20460
– ident: e_1_2_8_32_1
  doi: 10.18637/jss.v067.i01
– ident: e_1_2_8_47_1
  doi: 10.1167/iovs.17-23230
– ident: e_1_2_8_36_1
  doi: 10.1111/aos.14291
– ident: e_1_2_8_8_1
  doi: 10.1001/archneur.1984.04050170031011
– ident: e_1_2_8_18_1
  doi: 10.1093/brain/awm111
– ident: e_1_2_8_24_1
  doi: 10.1038/s41598-019-48388-7
– ident: e_1_2_8_3_1
  doi: 10.1212/WNL.0000000000009107
– ident: e_1_2_8_41_1
  doi: 10.1155/2012/384875
– ident: e_1_2_8_42_1
  doi: 10.1001/jamaophthalmol.2020.0959
– ident: e_1_2_8_26_1
  doi: 10.1007/s10792-018-0934-y
– ident: e_1_2_8_22_1
  doi: 10.1007/s00401-018-01956-z
– ident: e_1_2_8_25_1
  doi: 10.1002/mds.27914
– ident: e_1_2_8_33_1
  doi: 10.1002/mds.20914
– ident: e_1_2_8_37_1
  doi: 10.1002/acn3.767
SSID ssj0009610
Score 2.5711446
Snippet Objective This study was undertaken to analyze longitudinal changes of retinal thickness and their predictive value as biomarkers of disease progression in...
This study was undertaken to analyze longitudinal changes of retinal thickness and their predictive value as biomarkers of disease progression in idiopathic...
ObjectiveThis study was undertaken to analyze longitudinal changes of retinal thickness and their predictive value as biomarkers of disease progression in...
OBJECTIVEThis study was undertaken to analyze longitudinal changes of retinal thickness and their predictive value as biomarkers of disease progression in...
SourceID pubmedcentral
proquest
crossref
pubmed
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 165
SubjectTerms Adult
Atrophy
Biomarkers
Cognitive ability
Cognitive Dysfunction - complications
Cognitive Dysfunction - genetics
Confidence intervals
Dementia disorders
Evaluation
Female
Humans
Lewy bodies
Lewy Body Disease - genetics
Male
Middle Aged
Movement disorders
Mutation
Nerve Fibers - metabolism
Neurodegeneration
Neurodegenerative diseases
Optical Coherence Tomography
Parkinson Disease - complications
Parkinson Disease - congenital
Parkinson Disease - genetics
Parkinson's disease
Reduction
Retina
Retinal Ganglion Cells - metabolism
Risk
Thickness
Tomography
Tomography, Optical Coherence - methods
Visual Fields - genetics
Visual Fields - physiology
Title Retinal Thickness Predicts the Risk of Cognitive Decline in Parkinson Disease
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fana.25944
https://www.ncbi.nlm.nih.gov/pubmed/33098308
https://www.proquest.com/docview/2470493527/abstract/
https://search.proquest.com/docview/2454113487
https://pubmed.ncbi.nlm.nih.gov/PMC7756646
Volume 89
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1RS-QwEB72PJB7OfS8O6veEcWHe6mmyaTZck-Lq8jBiiwKvpWkTXARuuKu__8m6bbrIgf3UgqZ0mYmk3yTyXwFOPXSUmjscvI07lM0mU2NMj4tnPOB4atSMRUzucmv7_HPg3oYwO-uFqblh-g33IJnxPk6OLixi_M1aahpzBlhd8QP8JFgzTAMaYG3a8bdPFIRhDxbqjKJHa0QF-f9o5uL0TuE-f6g5FsAG1egqx34vIKObNTaehcGrvkC25NVcnwPJtNQvkwSd4-z6ilMYez2JbQuF4xgHpvOFk9s7tlFd2KIjV0ojHRs1rBQ_RwLwdi4Tdl8hfury7uL63T1t4S0QpSYasGtNJUVyuS2KhwKTV2kiMPaujBe-Ry18lwLl1c1R58JXevCel9Zx2Ul5DfYauaN2wcW0m3a1dRvXiNFXIUpuPeZsqgNd84mcNKprXxuSTHKlv5YlKTbMuo2gaNOoeXKLxalQE0hCYE-ncBx30wjOqQpTOPmr0FGYUYGG5LM91b__Vuk5MVQ8mECesMyvUBgy95saWaPkTVba0KumCfwK9rw3x9ejm5G8ebg_0UP4ZMIh13i3swRbC1fXt0PQitL-zOOSrqOp-Iv7fXmhg
link.rule.ids 230,315,786,790,891,1382,11589,27957,27958,46087,46329,46511,46753
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED-NIQEvjK9B2ACDeOAlneOPuJF4qTamAmuFqk7aC4psx9aqSila2xf-es5Ok9FNkxBvkXxWHJ_P_p3v7heAj54bdI1djpZGfSp0ZlIttU8L53xg-LIyhmJG43x4Lr5dyIsd-NzWwjT8EN2FW7CMuF8HAw8X0kfXrKG61j0E70Lcg_to7jI6VJNr8qgij1wEIdCWyoyLlleIsqOu6_ZpdAti3s6U_BvBxiPodA9-toNvMk_mvfXK9OzvG7yO__t1T-DxBpuSQbOYnsKOq5_Bg9Em-v4cRpNQH40S08uZnYc9kvy4Cq2rJUEcSSaz5ZwsPDluU5LIiQuVl47MahLKq2OlGTlpYkIv4Pz0y_R4mG5-x5BaIbhIFaOGa2uY1LmxhRNM4fjQpTGmKrSXPhdKeqqYy21Fhc-YqlRhvLfGUW4Z34fdelG7V0BCPE-5CueVVgJdukIX1PtMGqE0dc4k8KFVS_mrYd0oG35lVuLElHFiEjhsFVZuDG9ZMqHQ50FUqRJ43zWjyYQ4iK7dYh1kpMhwQfRR5mWj3-4tnNOiz2k_AbWl-U4g0HFvt9Szy0jLrRRCY5En8Ckq9u6Bl4PxID68_nfRd_BwOB2dlWdfx98P4BELmTXxIugQdldXa_cGodHKvI0W8AcC3QnC
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Ra9swED66Fspextatm7du1cYe-uJVlk5WTJ9Cs9BuSwilhb4ZyZZoKDilSf__TnLsNpTB3gw6YetOJ32n030G-O6lpdDY5eRp3KdoMpsaZXxaOOcDw1elYipmMs3PrvDXtbregpOuFqblh-gP3IJnxPU6OPhd7Y8fSUNNY34Qdkd8ATuY80GIvATOHhl380hFEPJsqcokdrRCXBz3XTc3o2cI8_lFyacANu5A49fwag0d2bC19RvYcs0e7E7WyfG3MLkI5cskcXkzr27DEsZm96F1tWQE89jFfHnLFp6ddjeG2MiFwkjH5g0L1c-xEIyN2pTNO7ga_7w8PUvXf0tIK0SJqRbcSlNZoUxuq8Kh0DREijisrQvjlc9RK8-1cHlVc_SZ0LUurPeVdVxWQu7DdrNo3AdgId2mXU3j5jVSxFWYgnufKYvacOdsAt86tZV3LSlG2dIfi5J0W0bdJnDQKbRc-8WyFKgpJCHQpxP42jfTjA5pCtO4xUOQUZiRwQYk877Vf_8WKXkxkHyQgN6wTC8Q2LI3W5r5TWTN1pqQK-YJHEUb_vvDy-F0GB8-_r_oIezORuPyz_n09yd4KcK9l3hMcwDbq_sH95mAy8p-iRP0L5BK6DA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Retinal+Thickness+Predicts+the+Risk+of+Cognitive+Decline+in+Parkinson+Disease&rft.jtitle=Annals+of+neurology&rft.au=Murueta-Goyena%2C+Ane&rft.au=Del+Pino%2C+Roc%C3%ADo&rft.au=Gald%C3%B3s%2C+Marta&rft.au=Arana%2C+Bego%C3%B1a&rft.date=2021-01-01&rft.eissn=1531-8249&rft.volume=89&rft.issue=1&rft.spage=165&rft_id=info:doi/10.1002%2Fana.25944&rft_id=info%3Apmid%2F33098308&rft.externalDocID=33098308
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0364-5134&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0364-5134&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0364-5134&client=summon